Active substance master file procedure

  • Email
  • Help

This guideline applies to human and veterinary medicines.

Current effective version

Revision 3 - Adopted guideline

Reference number

CHMP/QWP/227/02 Rev. 3/Corr.

EMEA/CVMP/134/02 Rev. 3/Corr.

Effective from01/10/2012
KeywordsActive substance master file (ASMF), letter of access, submission letter, common technical document (CTD)
DescriptionThis document assists in the compilation of the active substance section of the dossiers for a marketing authorisation application or a marketing-authorisation variation of a medicinal product. It is also intended to help active substance master file (ASMF) holders in the compilation of their ASMFs. Read together with additional guidance.

Document history

Revision 3

Current version

Adopted guideline

Additional guidance

Template (annexes)

Overview of comments

Draft guideline

In operation: 01/10/2012–present

Published: 01/10/2012

Published: 13/07/2012

Published: 13/07/2012

Published: 19/01/2012

Revision 2Draft guidelinePublished: 27/04/2005
Revision 1Adopted guidelineIn operation: 31/08/2004–30/09/2012

Related content

How helpful is this page?

Average rating:

 Based on 38 ratings

Add your rating:

See all ratings
7 ratings
6 ratings
6 ratings
7 ratings
12 ratings

Tell us more